Given that toremifene is primarily used in postmenopausal women as opposed to tamoxifen whose use is recommended in both pre- and post-menopausal women with ER/PR positive breast cancer [11], toremifene users tend to be older than tamoxifen users, which may have played a role in differential outcomes per SERM agent. The gene discussed is ESR1; the disease is breast cancer.